Gaps between European Crohn&apos;s Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

Inflammatory Bowel Disease

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

J Crohns Colitis

Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB

doi: 10.1093/ecco-jcc/jjaf060

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

J Crohns Colitis

Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S

doi: 10.1093/ecco-jcc/jjaf052

Inflammatory Bowel Disease

Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study

Clin Gastroenterol Hepatol

Devi J, Xu A, Stone M, Patel A, Khan A, Reddy N, Klein J, Chowla N, Benson C, Luu BC, Huang K, Jaiprada F, Fenster M, Ungaro R, Pekow J, Johnson AM, Yarur AJ, Shukla R, Huecker J, Bishu S, REBOOT IBD consortium, Deepak P

doi: 10.1016/j.cgh.2025.01.012

Inflammatory Bowel Disease

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Inflamm Bowel Dis

Ertem FU, Rivers CR, Ghaffari AA, Watson AR, Tang G, Schwartz M, Johnston E, Barrie A, Harrison J, Dueker JM, Hartman D, Binion DG

doi: 10.1093/ibd/izae137

Inflammatory Bowel Disease

Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort - an Epi-IBD cohort study

J Crohns Colitis

Wewer MD, Lophaven S, Lakatos PL, Gonczi L, Salupere R, Kievit HAL, Nielsen KR, Midjord J, Domislovic V, Krznarić Ž, Pedersen N, Kjeldsen J, Halfvarson J, Sebastian S, Goldis A, Arebi N, Oksanen P, Neumann A, Andersen V, Katsanos KH, Koukoudis A, Turcan S, Ellul P, Kupcinskas J, Kiudelis G, Fumery M, Kaimakliotis IP, D'Inca R, Lombardini S, Hernandez V, Fernandez A, Langholz E, Munkholm P, Burisch J, Epi-IBD-group

doi: 10.1093/ecco-jcc/jjaf089

Further Publications

Inter-Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five-Nations Survey Study

United European Gastroenterol J

Ukashi O, Amiot A, Laharie D, Menchén L, Gutiérrez A, Fernandes S, Pessarelli T, Correia F, Gonzalez-Muñoza C, López-Cardona J, Calabrese G, Ferreiro-Iglesias R, Tamir-Degabli N, Dussias NK, Mousa A, Oliveira R, Richard N, Veisman I, Sharif K, Ben-Horin S, Soutullo-Castiñeiras C, Dragoni G, Rotulo S, Favale A, Calméjane L, Bazin T, Elosua A, Lopes S, Felice C, Mauriz V, Rodrigues IC, Jougon J, Botto I, Tavares de Sousa H, Bertani L, Abadía PR, Bernardi A, Zabana Y, Serra-Ruiz X, Viola A, Barreiro-de Acosta M, Yanai H, Armuzzi A, Magro F, Kopylov U

doi: 10.1002/ueg2.12757

Inflammatory Bowel Disease

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

Adv Ther

Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, Kerner C, Pilon D

doi: 10.1007/s12325-024-02963-1

Inflammatory Bowel Disease

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study

Am J Gastroenterol

Lee SD, Vermeire S, Ungaro R, Vadhariya A, Durand F, Morris N, Yu G, Fisher DA, Traxler K, Long M

doi: 10.14309/ajg.0000000000003410

Gastroenterology

Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

Related content

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort - an Epi-IBD cohort study

Inter-Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five-Nations Survey Study

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study